Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.

< BACK TO ARCHIVE


Papers: 28 Nov 2020 - 4 Dec 2020


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2020 Dec 03


Cephalalgia


http://www.ncbi.nlm.nih.gov/pubmed/33269951?dopt=Abstract

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.

Authors

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Zhang F, Rippon GA, Cheng S, Mikol DD
Cephalalgia. 2020 Dec 03:333102420973994.
PMID: 33269951.

Abstract

To determine reversion rates from chronic migraine to episodic migraine during long-term erenumab treatment.
Read This Paper